Adipose-derived Mesenchymal Stem Cells in Osteoarthritis

Effectiveness of Adipose-derived Mesenchymal Stem Cells in Patients With Osteoarthritis of the Knee, Hip or Glenohumeral Joint and Analysis of the Regeneration Processes Based on Inflammatory Markers, microRNAs and Clinical Features.

This phase I/II study will enroll 100 subjects with mild to moderate osteoarthritis of the hip/knee/glenohumeral joints will be enrolled according to strict inclusion and exclusion criteria. Subjects will receive a single dose of at least 10 million of autologous Adipose-derived Mesenchymal Stem Cells (ADMCS) every three months for 12 months (maximum four doses in total and at least 40 million of ADMCS in total) via ultrasound guided intra-articular injection.

Study Overview

• Status: Unknown
• Conditions: Osteoarthritis; Knee Osteoarthritis; Hip Osteoarthritis; Glenohumeral Osteoarthritis
• Intervention / Treatment: Biological: Intra-articular injection of ADMSC

Detailed Description

This phase I/II study will enroll 100 subjects with mild to moderate osteoarthritis of the hip/knee/ glenohumeral joint will be enrolled according to strict inclusion and exclusion criteria. All patients will be selected and sign consent forms, then divided into 3 groups based on clinical presentation. Participants will be exposed to abdominal liposuction procedure under local anesthesia for adipose-derived mesenchymal stem cells (ADMSC) harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in the Polish Stem Cell Bank. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under ultrasound guidance at the theater under spinal anesthesia. Each patient will receive a single dose of at least 10 million of ADMSC in 3 mL of normal saline every three months for 12 months (maximum four doses in total and at least 40 million of ADMSC in total) via ultrasound guided intra-articular injection. During the study period and 24 months after last injection they will be followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected joint. The local and systemic safety of the procedure and therapy with ADMSC will be also determined during study.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Marek Postula, MD, PhD; Phone Number: +48605113346; Email: mpostula@wum.edu.pl
• Study Contact Backup: Name: Robert Śmigielski, MD, PhD; Phone Number: +48609455055; Email: rsmigielski@gmail.com

Study Locations

• Poland
  • Mazovian
    • Warsaw, Mazovian, Poland, 00-132
      • Recruiting
      • Life Clinic
      • Contact: Robert Śmigielski, MD; Phone Number: +48609455055
      • Contact: Robert Śmigielski

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 28 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• presence of osteoarthritis of the knee, hip or glenohumeral joint
• confirmation cartilage injury, articular cartilage part or full-thickness injury by MR (Magnetic Resonance)
• joint pain of VAS (visual analog scale score) is 1 or higher while resting, 2 and higher during any physical activity
• loss of joint function based on scale specific for certain joints; for hip: HHS scale (Harris Hip Score), HOOS scale (Hip disability and Osteoarthritis Outcome Score), The Western Ontario and McMaster Universities Arthritis Index (WOMAC); for knee: modified HHS score (Harris Hip Score), The Western Ontario and McMaster Universities Arthritis Index (WOMAC), The International Knee Documentation Committee (IKDC Questionnaire) and KOOS scale (Osteoarthritis Outcome Score); glenohumeral joint: Disability of Arm, Shoulder and Hand [DASH], CONSTANT score
• clinical indication for surgical intervention
• no effect of pharmacotherapy according to The World Health Organization (WHO) analgesic ladder lasting at least 6 months
• no effect of physical rehabilitation lasting at least 6 months
• willing to participate understand and sign the consent form of this study

Exclusion Criteria:

• active inflammatory disease or infection,
• skin disease/infection around joint,
• severe heart failure,
• anemia,
• active/history of human immunodeficiency viruses (HIV), the hepatitis B virus (HBV) or the hepatitis C virus (HCV) infection,
• pregnant or breast-feeding women,
• mental disease, addiction to drugs or alcohol,
• participate other clinical experiments in 6 months,
• refuse to sign the consent form, or cannot keep follow-up visit.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: osteoarthritis of the knee; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)	Biological: Intra-articular injection of ADMSC; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
Active Comparator: osteoarthritis of the hip; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)	Biological: Intra-articular injection of ADMSC; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
Active Comparator: osteoarthritis of the glenohumeral joint; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)	Biological: Intra-articular injection of ADMSC; Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)	Change in hip disability and osteoarthritis outcome score (HOOS) score. HOOS consists of 5 subscales: pain, other symptoms, function in activities of daily living (ADL), and function in sport and recreation (Sport/Rec), and hip-related quality of life (QOL). In total, 40 items: 10 items for pain, 5 items for other symptoms (3 for symptoms and 2 for stiff- ness), 17 items for function in ADL, 4 items for function in Sport/Rec, and 4 items for hip-related QOL. Standardized answer options are given (5 Likert boxes) and each question is scored from 0 to 4. Scores are summarized for each subscale and trans- formed to a 0-100 scale (0 indicating extreme problems and 100 indicating no problems).	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
Harris Hip Score	Change in Harris Hip Score (HHS) score. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
Knee injury and Osteoarthritis Outcome Score (KOOS)	Change in Knee injury and Osteoarthritis Outcome Score (KOOS). It holds 42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL) The five patient-relevant subscales of KOOS are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic assessment scales and generic measures.	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
modified Harris Hip Score for knee	Change in modified Harris Hip Score (mHHS) score. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
The International Knee Documentation Committee (IKDC Questionnaire)	Change in IKDC Questionnaire score. The questionnaire looks at 3 categories: symptoms, sports activity, and knee function. The symptoms subscale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee. Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function The transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms.	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
WOMAC (for hip and knee)	Change in WOMAC score. WOMAC score is used to assess patients with osteoarthritis of the hip or knee using 24 parameters in 5 categories. 1 Pain 2.Stiffness 3.Physical function 4.Social function 5. Emotional function Scoring and Interpretation Response : points none - 0 slight 1 moderate 2 severe 3 extreme 4 score = = summary (points for relevant items) average score = = (total score) / (number of items) Interpretation: minimum total score: 0 maximum total score: 96 minimum pain subscore: 0 maximum pain subscore: 20 minimum stiffness subscore: 0 maximum stiffness subscore: 8 minimum physical function subscore: 0 maximum physical function subscore: 6	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
Disability of Arm, Shoulder and Hand [DASH]	Change in DASH score. DASH outcome measure is a 30-item. The items enquire about the degree of difficulty in performing different physical activities because of arm, shoulder and hand problems (21 items), the severity of each of the symptoms of pain, activity-related pain, tingling, weakness and stiffness (five items) and the impact of the problem on social functioning, work, sleep and self-image (four items). The scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability A minimum score is 30; a maximum is 150. The range of the scores, therefore-from 30 to 150-equals 120. The raw score is then transformed to a zero-to-100 scale with zero reflecting no disability (good function) and 100 reflecting maximum disability.	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
The Constant-Murley score (CMS)	Change in CMS score. CMS is a 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient The test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points). The higher the score, the higher the quality of the function.	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
Visual Analog Scale (VAS)	Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles. Visual analogue scales (VAS) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid (statistically measurable and reproducible) classification of symptom severity and disease control The VAS is a commonly used tool in health outcome studies, when using it to assess importance of certain action or intervention, how we can interpret the results, on 1 to 10 line (where 1; the least and the 10; the highest)	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nature, incidence and severity of adverse events (AEs)	Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship. Methods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups. Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship. Methods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups	Time Frame: Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)
Change in cartilage thickness	Cartilage thickness on MRI in mm	Baseline, and 12 months post-treatment cycle
Change in cartilage volume	Cartilage volume on MRI in ml	Baseline, and 12 months post-treatment cycle
Change in cartilage morphology	Cartilage morphology on MRI. Change in the International Cartilage Repair Society (ICRS) classification. It is based on grading of cartilage lesions, in which lesions are graded 0 to 4 based on depth of the lesion. Grade 1 and 2 lesions have excellent prognosis. Grade 2 and 3 lesions may benefit from cartilage debridement or other more conservative surgical measures. Grade 4 lesions extend into the subchondral bone and may require bone grafting if bony cavitation is extensive	Baseline, and 12 months post-treatment cycle
Change in subchondral bone morphology	Subchondral bone morphology (i.e. edema) on MRI	Baseline, and 12 months post-treatment cycle
Inflammation monitoring	Baseline, and 12 months post-treatment cycle based on changes of concentrations of interleukin (IL)-1β (pg/ml), IL-6 (pg/ml), IL-8 (pg/ml), IL-11 (pg/ml), tumor necrosis factor (TNF)-alpha (pg/ml)	Baseline, and 12 months post-treatment cycle]
Inflammation monitoring	Baseline, and 12 months post-treatment cycle based on changes of concentrations of CD40L (ng/ml)	Baseline, and 12 months post-treatment cycle
Inflammation monitoring	Baseline, and 12 months post-treatment cycle based on changes of high-sensitivity C-reactive protein (hsCRP ) (mg/dl)	Baseline, and 12 months post-treatment cycle
Inflammation monitoring	Baseline, and 12 months post-treatment cycle based on changes of miRNA expression (ug/dl) defined on microarray profiling	Baseline, and 12 months post-treatment cycle

Collaborators and Investigators

• Sponsor: Medical University of Warsaw
• Investigators: Principal Investigator: Marek Postula, MD, PhD, Medical University of Warsaw; Study Director: Robert Smiegielski, MD, Life Clinic

Study record dates

Study Major Dates

• Study Start (Anticipated): April 5, 2019
• Primary Completion (Anticipated): March 1, 2020
• Study Completion (Anticipated): March 20, 2022

Study Registration Dates

• First Submitted: March 4, 2019
• First Submitted That Met QC Criteria: March 7, 2019
• First Posted (Actual): March 11, 2019

Study Record Updates

• Last Update Posted (Actual): April 9, 2019
• Last Update Submitted That Met QC Criteria: April 8, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: osteoarthritis; Adipose-derived Mesenchymal Stem Cells
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Osteoarthritis, Hip
• Other Study ID Numbers: 002/LIFE/2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No